RemeGen Co., Ltd. (OTCMKTS:REGMF – Get Free Report) was the target of a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 1,131,607 shares, an increase of 67.8% from the May 14th total of 674,500 shares. Based on an average trading volume of 0 shares, the short-interest ratio is currently ∞ days.
RemeGen Stock Performance
REGMF stock remained flat at $9.50 during trading hours on Wednesday. The firm’s fifty day moving average is $11.17 and its 200-day moving average is $10.55. RemeGen has a 12-month low of $9.50 and a 12-month high of $15.91.
RemeGen Company Profile
RemeGen Co, Ltd. is a Shanghai-based biopharmaceutical company focused on the research, development and commercialization of innovative antibody-based therapeutics for oncology and immunology. Since its founding in 2009, RemeGen has built a portfolio of antibody–drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies aimed at addressing a range of solid tumors and immune-related conditions. The company leverages its in-house discovery, engineering and manufacturing capabilities to advance its pipeline from preclinical stages through clinical trials.
RemeGen’s lead product candidate, Disitamab Vedotin (RC48), is a HER2-targeting ADC that has received regulatory approval in China for HER2-positive gastric cancer and urothelial carcinoma.
Read More
- Five stocks we like better than RemeGen
- Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan
- Flying Under the Radar: Lockheed Martin’s $2.8B Stealth Setup
- Bread’s Comeback Is Real—But Is the Easy Money Gone?
- Ollie’s Stock Has Lagged Despite Earnings Beats—What’s Holding It Back?
Receive News & Ratings for RemeGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RemeGen and related companies with MarketBeat.com's FREE daily email newsletter.
